Compile Data Set for Download or QSAR
Report error Found 96 Enz. Inhib. hit(s) with all data for entry = 1534
TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330062(US9663529, Example I-1 | 2-(2-Chlorophenyl)-N-(5H-...)
Affinity DataIC50: 5.97nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330071(US9663529, Example I-10 | 2-(2-chloro-4- fluorophe...)
Affinity DataIC50: 6.27nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330067(US9663529, Example I-6 | (R)-2-amino-N- (5H-chrome...)
Affinity DataIC50: 9.43nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330156(US9663529, Example IV-4 | 2-Phenyl-N-(9H-pyrido[3,...)
Affinity DataIC50: 9.5nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330085(US9663529, Example I-24 | N-(5H-chromeno[3,4- c]py...)
Affinity DataIC50: 11.1nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330076(US9663529, Example I-15 | N-(5H-chromeno[3,4- c]py...)
Affinity DataIC50: 16.7nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330070(US9663529, Example I-9 | (R)-2-amino-N-(5H- chrome...)
Affinity DataIC50: 19.9nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330155(US9663529, Example IV-3 | 2-(3-Fluorophenyl)-N-(9H...)
Affinity DataIC50: 21nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM263022((S)-2-amino-N-(5H-chromeno[3,4-c]pyridin-8-yl)-2-p...)
Affinity DataIC50: 21.8nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330072(US9663529, Example I-11 | 2-(3-chlorophenyl)- N-(5...)
Affinity DataIC50: 24.8nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330066(US9663529, Example I-5 | 2-(2-chlorophenyl)- N-(5H...)
Affinity DataIC50: 33.5nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330078(US9663529, Example I-17 | N-(5H-chromeno[3,4- c]py...)
Affinity DataIC50: 37.8nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330087(US9663529, Example I-26 | N-(5H-chromeno[3,4- c]py...)
Affinity DataIC50: 38.7nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330121(US9663529, Example I-60 | N-(5H-chromeno[3,4- c]py...)
Affinity DataIC50: 40.4nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330123(US9663529, Example I-62 | N-(5H-chromeno[3,4- c]py...)
Affinity DataIC50: 43.6nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330154(US9663529, Example IV-2 | 2-(3-Chlorophenyl)-N-(9H...)
Affinity DataIC50: 46.3nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330153(US9663529, Example IV-1 | 3-(3-Methoxyphenyl)-N-(9...)
Affinity DataIC50: 50.9nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330107(US9663529, Example I-46 | N-(5H-chromeno[3,4- c]py...)
Affinity DataIC50: 51.2nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330075(US9663529, Example I-14 | N-(5H-chromeno [3,4-c]py...)
Affinity DataIC50: 54.4nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330069(US9663529, Example I-8 | (S)-2-amino-N-(5H- chrome...)
Affinity DataIC50: 55.6nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330108(US9663529, Example I-47 | N-(5H-chromeno[3,4- c]py...)
Affinity DataIC50: 56.2nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330133(US9663529, Example I-72 | N-(5H-chromeno[3,4- c]py...)
Affinity DataIC50: 58.7nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330088(US9663529, Example I-27 | N-(5H-chromeno[3,4- c]py...)
Affinity DataIC50: 60.8nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330073(US9663529, Example I-12 | N-(5H-chromeno[3,4- c]py...)
Affinity DataIC50: 74.5nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330063(US9663529, Example I-2 | N-(5H-chromeno[3,4- c]pyr...)
Affinity DataIC50: 82.2nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330077(US9663529, Example I-16 | N-(5H-chromeno[3,4- c]py...)
Affinity DataIC50: 110nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330119(US9663529, Example I-58 | N-(5H-chromeno[3,4- c]py...)
Affinity DataIC50: 111nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330065(US9663529, Example I-4 | (R)-2-amino-N-(5H- chrome...)
Affinity DataIC50: 128nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330150(US9663529, Example III-4 | benzyl 5H- chromeno[3,4...)
Affinity DataIC50: 133nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330074(US9663529, Example I-13 | 2-(4-chlorophenyl)- N-(5...)
Affinity DataIC50: 134nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330083(US9663529, Example I-22 | N-(5H-chromeno[3,4- c]py...)
Affinity DataIC50: 159nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330082(US9663529, Example I-21 | N-(5H-chromeno[3,4- c]py...)
Affinity DataIC50: 161nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330137(US9663529, Example II-3 | 1-(5H-chromeno[3,4- c]py...)
Affinity DataIC50: 189nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330097(US9663529, Example I-36 | N-(5H-chromeno [3,4-c]py...)
Affinity DataIC50: 204nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330095(US9663529, Example I-34 | N-(5H-chromeno[3,4- c]py...)
Affinity DataIC50: 207nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330141(US9663529, Example II-7 | 1-(5H-chromeno[3,4- c]py...)
Affinity DataIC50: 233nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330144(US9663529, Example II-10 | 1-(3-chlorophenethyl)- ...)
Affinity DataIC50: 248nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330064(US9663529, Example I-3 | (S)-2-amino-N-(5H- chrome...)
Affinity DataIC50: 284nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330103(US9663529, Example I-42 | N-(5H-chromeno[3,4- c]py...)
Affinity DataIC50: 287nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330086(US9663529, Example I-25 | N-(5H-chromeno[3,4- c]py...)
Affinity DataIC50: 295nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330132(US9663529, Example I-71 | N-(5H-chromeno[3,4- c]py...)
Affinity DataIC50: 316nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330098(US9663529, Example I-37 | 3-(4-chlorophenyl)- N-(5...)
Affinity DataIC50: 323nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330129(US9663529, Example I-68 | N-(5H-chromeno[3,4- c]py...)
Affinity DataIC50: 362nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330094(US9663529, Example I-33 | N-(5H-chromeno[3,4- c]py...)
Affinity DataIC50: 367nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330084(US9663529, Example I-23 | N-(5H-chromeno[3,4- c]py...)
Affinity DataIC50: 368nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330157(US9663529, Example IV-5 | 2-(3-Cyanophenyl)-N-(9H-...)
Affinity DataIC50: 383nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330135(US9663529, Example II-1 | N-(5H-Chromeno[3,4-c]pyr...)
Affinity DataIC50: 387nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330079(US9663529, Example I-18 | N-(5H-chromeno[3,4- c]py...)
Affinity DataIC50: 393nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330096(US9663529, Example I-35 | 3-acetamido-N-(5H- chrom...)
Affinity DataIC50: 434nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM330128(US9663529, Example I-67 | N-(5H-chromeno[3,4- c]py...)
Affinity DataIC50: 471nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 96 total ) | Next | Last >>
Jump to: